• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

COPD 中与严重肺动脉高压相关的流行率和预测因素。

Prevalence and predictors associated with severe pulmonary hypertension in COPD.

机构信息

Associate Professor of Pulmonology Cardiovascular Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran.

Assistant Professor of Emergency Medicine, Department of Emergency Medicine, Kerman University of Medical Sciences, Clinical Research Center, Afzalipour Hospital, Kerman, Iran.

出版信息

Am J Emerg Med. 2018 Feb;36(2):277-280. doi: 10.1016/j.ajem.2017.08.014. Epub 2017 Aug 5.

DOI:10.1016/j.ajem.2017.08.014
PMID:28797558
Abstract

BACKGROUND

Pulmonary hypertension (PH) is one of the most common complications of COPD (chronic obstructive pulmonary disease), but its severe form is uncommon. Various factors play an important role in the occurrence and severity of pulmonary hypertension in patients.

METHODS

This cross-sectional study was performed on patients with COPD referred to an emergency department over a one-year period. The tests-including complete blood count (CBC) and arterial blood gas (ABG), pulmonary functional test (PFT) and echocardiography-were performed for all patients to measure mPAP (mean pulmonary artery pressure), ejection fraction (EF) and body mass index (BMI). The prevalence of severe pulmonary hypertension and its associated factors were investigated in these patients.

RESULTS

A total of 1078 patients was included in the study, of whom 628 (58.3%) were male and 450 (41.7%) were female. The mean age of the patients undergoing the study was 70.1±12.2. A total of 136 (13.7%) of them had mPAP (mm Hg)≥40mm Hg as severe pulmonary hypertension. Following multivariable analysis by using the backward conditional method, it was shown that seven variables had a significant correlation with severe PH.

CONCLUSIONS

The results showed that there is an independent correlation between hypoxia, hypopnea and compensatory metabolic alkalosis, polycythemia, left ventricular dysfunction, emaciation, and cachectic with severe pulmonary hypertension. The prevalence of severe PH in these patients was 13.7%.

摘要

背景

肺动脉高压(PH)是 COPD(慢性阻塞性肺疾病)最常见的并发症之一,但严重形式并不常见。各种因素在患者肺动脉高压的发生和严重程度中起重要作用。

方法

这是一项为期一年的回顾性研究,对因 COPD 而到急诊就诊的患者进行了研究。对所有患者进行了包括全血细胞计数(CBC)和动脉血气分析(ABG)、肺功能测试(PFT)和超声心动图在内的检查,以测量平均肺动脉压(mPAP)、射血分数(EF)和体重指数(BMI)。调查了这些患者中严重肺动脉高压的患病率及其相关因素。

结果

共有 1078 名患者纳入研究,其中 628 名(58.3%)为男性,450 名(41.7%)为女性。研究对象的平均年龄为 70.1±12.2 岁。共有 136 名(13.7%)患者 mPAP(mmHg)≥40mmHg,为严重肺动脉高压。采用后向条件法进行多变量分析后,有 7 个变量与严重 PH 有显著相关性。

结论

结果表明,缺氧、呼吸暂停和代偿性代谢性碱中毒、红细胞增多症、左心室功能障碍、消瘦和恶病质与严重肺动脉高压之间存在独立相关性。这些患者中严重 PH 的患病率为 13.7%。

相似文献

1
Prevalence and predictors associated with severe pulmonary hypertension in COPD.COPD 中与严重肺动脉高压相关的流行率和预测因素。
Am J Emerg Med. 2018 Feb;36(2):277-280. doi: 10.1016/j.ajem.2017.08.014. Epub 2017 Aug 5.
2
CT evaluation of small pulmonary vessels area in patients with COPD with severe pulmonary hypertension.CT 评价 COPD 合并重度肺动脉高压患者的小肺血管面积。
Thorax. 2016 Sep;71(9):830-7. doi: 10.1136/thoraxjnl-2015-207696. Epub 2016 Apr 15.
3
Pulmonary arterial lesions in explanted lungs after transplantation correlate with severity of pulmonary hypertension in chronic obstructive pulmonary disease.移植肺中肺动脉病变与慢性阻塞性肺疾病肺动脉高压的严重程度相关。
J Heart Lung Transplant. 2013 Mar;32(3):347-54. doi: 10.1016/j.healun.2012.11.014. Epub 2012 Dec 21.
4
Systemic inflammation in patients with COPD and pulmonary hypertension.慢性阻塞性肺疾病(COPD)合并肺动脉高压患者的全身炎症
Chest. 2006 Aug;130(2):326-33. doi: 10.1378/chest.130.2.326.
5
Pulmonary Arterial Hypertension-Specific Drug Therapy in COPD Patients with Severe Pulmonary Hypertension and Mild-to-Moderate Airflow Limitation.慢性阻塞性肺疾病(COPD)合并重度肺动脉高压和轻至中度气流受限患者的肺动脉高压特异性药物治疗
Respiration. 2016;91(1):9-17. doi: 10.1159/000441304. Epub 2015 Oct 23.
6
Pulmonary artery pressure and PaO2 in chronic obstructive pulmonary disease.慢性阻塞性肺疾病患者的肺动脉压和 PaO2。
Respir Med. 2013 Aug;107(8):1271-9. doi: 10.1016/j.rmed.2013.03.021. Epub 2013 Jun 12.
7
Hemodynamic and gas exchange effects of inhaled iloprost in patients with COPD and pulmonary hypertension.吸入伊洛前列素对慢性阻塞性肺疾病合并肺动脉高压患者血流动力学和气体交换的影响。
Int J Chron Obstruct Pulmon Dis. 2017 Nov 22;12:3353-3360. doi: 10.2147/COPD.S141798. eCollection 2017.
8
Impact of chronic obstructive pulmonary disease with pulmonary hypertension on both left ventricular systolic and diastolic performance.慢性阻塞性肺疾病合并肺动脉高压对左心室收缩和舒张功能的影响。
J Am Soc Echocardiogr. 2005 Aug;18(8):873-81. doi: 10.1016/j.echo.2005.01.016.
9
Pulmonary hypertension in chronic lung diseases.慢性肺部疾病相关肺动脉高压。
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D109-16. doi: 10.1016/j.jacc.2013.10.036.
10
Can ADMA play a role in determining pulmonary hypertension related to chronic obstructive pulmonary disease?非对称性二甲基精氨酸在慢性阻塞性肺疾病相关性肺动脉高压的发生中是否起作用?
Clin Respir J. 2018 Apr;12(4):1433-1438. doi: 10.1111/crj.12675. Epub 2017 Aug 11.

引用本文的文献

1
Phase 1 Study of MK-5475, an Inhaled Soluble Guanylate Cyclase Stimulator, in Participants with Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease.MK-5475,一种吸入型可溶性鸟苷酸环化酶刺激剂,在与慢性阻塞性肺疾病相关的肺动脉高压患者中的 1 期研究。
Int J Chron Obstruct Pulmon Dis. 2024 May 23;19:1105-1121. doi: 10.2147/COPD.S454905. eCollection 2024.
2
Chronic obstructive pulmonary disease burden, grades and erythrocytosis at a tertiary hospital in western Uganda.乌干达西部一家三级医院的慢性阻塞性肺疾病负担、分级和红细胞增多症。
BMC Pulm Med. 2024 Mar 6;24(1):119. doi: 10.1186/s12890-024-02944-8.
3
Clinical characteristics and predictors of pulmonary hypertension in chronic obstructive pulmonary disease at different altitudes.
不同海拔地区慢性阻塞性肺疾病患者肺动脉高压的临床特征及其预测因素。
BMC Pulm Med. 2023 Apr 18;23(1):127. doi: 10.1186/s12890-023-02405-8.
4
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary.全球慢性阻塞性肺疾病倡议 2023 年报告:GOLD 执行摘要。
Eur Respir J. 2023 Apr 1;61(4). doi: 10.1183/13993003.00239-2023. Print 2023 Apr.
5
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary.慢性阻塞性肺疾病全球倡议组织2023年报告:《慢性阻塞性肺疾病全球倡议》执行摘要
Am J Respir Crit Care Med. 2023 Apr 1;207(7):819-837. doi: 10.1164/rccm.202301-0106PP.
6
Efficacy of computed tomography in diagnosing pulmonary hypertension: A systematic review and meta-analysis.计算机断层扫描在诊断肺动脉高压中的效能:一项系统评价与荟萃分析
Front Cardiovasc Med. 2022 Oct 5;9:966257. doi: 10.3389/fcvm.2022.966257. eCollection 2022.
7
The Association of Body Mass Index With the Risk of Pulmonary Hypertension in Adults: A Systematic Review and Meta-Analysis of Observational Studies.成人身体质量指数与肺动脉高压风险的关联:观察性研究的系统评价和荟萃分析
Front Med (Lausanne). 2022 Jan 25;8:680223. doi: 10.3389/fmed.2021.680223. eCollection 2021.
8
Obstructive Sleep Apnea is Associated with an Increased Prevalence of Polycythemia in Patients with Chronic Obstructive Pulmonary Disease.阻塞性睡眠呼吸暂停与慢性阻塞性肺疾病患者红细胞增多症的患病率增加有关。
Int J Chron Obstruct Pulmon Dis. 2022 Jan 15;17:195-204. doi: 10.2147/COPD.S338824. eCollection 2022.
9
NT-pro BNP in AECOPD-PH: old biomarker, new insights-based on a large retrospective case-controlled study.NT-proBNP 在 AECOPD-PH 中的作用:基于一项大型回顾性病例对照研究的旧生物标志物、新认识。
Respir Res. 2021 Dec 27;22(1):321. doi: 10.1186/s12931-021-01917-3.
10
Secondary polycythemia in chronic obstructive pulmonary disease: prevalence and risk factors.慢性阻塞性肺疾病中的继发性红细胞增多症:患病率和危险因素。
BMC Pulm Med. 2021 Jul 14;21(1):235. doi: 10.1186/s12890-021-01585-5.